Neumora Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2020
Selling, General & Admin	67.13	62.54	45.48	31.12	24.55	8.39	Upgrade
Research & Development	197.42	200.93	142.72	91.75	55.78	17.31	Upgrade
Operating Expenses	264.54	263.46	188.19	122.87	80.32	25.71	Upgrade
Operating Income	-264.54	-263.46	-188.19	-122.87	-80.32	-25.71	Upgrade
Interest & Investment Income	13.19	19.93	16.61	4.56	-	-	Upgrade
Other Non Operating Income (Expenses)	-0.55	-0.08	-0.17	0.41	0.01	-0.08	Upgrade
EBT Excluding Unusual Items	-251.91	-243.61	-171.75	-117.9	-80.31	-25.79	Upgrade
Merger & Restructuring Charges	-	-	-	-	-	-0.7	Upgrade
Other Unusual Items	-	-	-	-	-	-3.28	Upgrade
Pretax Income	-251.91	-243.61	-235.66	-130.9	-237.31	-99.27	Upgrade
Income Tax Expense	0.18	0.18	0.27	-	-	-	Upgrade
Net Income	-252.09	-243.79	-235.93	-130.9	-237.31	-99.27	Upgrade
Net Income to Common	-252.09	-243.79	-235.93	-130.9	-237.31	-99.27	Upgrade
Shares Outstanding (Basic)	161	159	65	27	22	13	Upgrade
Shares Outstanding (Diluted)	161	159	65	27	22	13	Upgrade
Shares Change (YoY)	24.37%	145.12%	138.99%	24.25%	68.46%	-	Upgrade
EPS (Basic)	-1.57	-1.53	-3.63	-4.81	-10.84	-7.64	Upgrade
EPS (Diluted)	-1.57	-1.53	-3.63	-4.81	-10.84	-7.64	Upgrade
Free Cash Flow	-194.9	-182.94	-163.4	-115.41	-76.24	-28.06	Upgrade
Free Cash Flow Per Share	-1.21	-1.15	-2.51	-4.24	-3.48	-2.16	Upgrade
EBITDA	-264.06	-262.83	-187.53	-122.28	-79.79	-25.6	Upgrade
D&A For EBITDA	0.49	0.63	0.67	0.59	0.54	0.11	Upgrade
EBIT	-264.54	-263.46	-188.19	-122.87	-80.32	-25.71	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q